Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective study to evaluate survival of Multiple Myeloma patients who are refractory to both Bortezomib and Lenalidomide therapy.

Next Previous
X
Search
Trial Profile

A Retrospective study to evaluate survival of Multiple Myeloma patients who are refractory to both Bortezomib and Lenalidomide therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary) ; Panobinostat (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Feb 2019 New trial record
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top